Public Offering

  • AAR Announces Pricing of 3 Million Share Public Offering

    AAR CORP. (NYSE: AIR) announced the pricing of a public offering of 3,000,000 shares of common stock at $83.00 per share. Underwriters have an option to purchase up to 450,000 additional shares. Net proceeds, estimated at $239 million (potentially $274.9 million with the option), will primarily repay debt under its revolving credit facility and for general corporate purposes, including potential acquisitions. Goldman Sachs, Jefferies, and RBC Capital Markets are the joint lead book-running managers. The offering is expected to close around October 2, 2025.

    2025年9月30日
  • BioAffinity Technologies Completes $4.8 Million Public Offering

    bioAffinity Technologies announced the completion of a public offering, generating $4.8 million in gross proceeds. The offering included shares of common stock and pre-funded warrants. WallachBeth Capital, LLC served as the placement agent. bioAffinity focuses on non-invasive cancer diagnostics, including CyPath® Lung, a Laboratory Developed Test for early lung cancer detection. The company addresses the growing precision diagnostics market with a focus on improving patient outcomes through early diagnosis. The announcement contains forward-looking statements subject to risks detailed in SEC filings.

    2025年9月30日
  • Soligenix Announces Pricing of $7.5 Million Public Offering

    Soligenix, Inc. (SNGX) announced a public offering of 5,555,560 shares of common stock (or equivalents) with warrants at $1.35 per share/warrant. The warrants are immediately exercisable at $1.35, expiring in five years. Existing warrants for 1,162,064 shares will be amended to the same price and expiration. The offering, expected to close around September 29, 2025, aims to raise $7.5 million, which will fund R&D, commercialization, and general corporate needs. A.G.P./Alliance Global Partners is the sole placement agent. This offering is under an effective SEC registration statement.

    2025年9月26日
  • Mirion Technologies Announces Pricing of Upsized Public Offering

    Mirion Technologies (NYSE: MIR) announced the pricing of an upsized public offering of 17.3 million shares of Class A common stock at $21.35 per share, aiming to raise approximately $356.2 million. Simultaneously, they priced a $325 million convertible senior notes offering. Proceeds will fund capped call transactions related to the notes and the acquisition of Paragon Energy Solutions. The offerings are expected to close on September 30, 2025. Goldman Sachs and Evercore ISI are leading the common stock offering. These moves support Mirion’s growth strategy in radiation safety, science, and medicine.

    2025年9月25日
  • Wellgistics Health Announces Pricing of $5 Million Public Offering

    Wellgistics Health (WGRX) announced a $5 million public offering of 7,142,862 shares and warrants priced at $0.70 per share. Warrants are exercisable at $0.70 immediately and expire in five years. The offering, managed by H.C. Wainwright & Co., is expected to close around September 29, 2025. Proceeds will fund working capital, operating expenses, R&D, and potential acquisitions. The offering entails significant shareholder dilution.

    2025年9月25日
  • Reviva Pharmaceuticals Announces $9 Million Public Offering Pricing

    Reviva Pharmaceuticals (RVPH) announced a $9 million public offering of 27 million shares/equivalents, plus Series E & F warrants, priced at $0.335 per share. Proceeds will fund R&D and corporate purposes. The Series E warrants expire in 5 years, Series F in 12 months, both exercisable at $0.335. Expected closing is around Sept. 22, 2025. The offering, led by A.G.P./Alliance Global Partners, may lead to shareholder dilution, with potential for 54 million additional warrant shares.

    2025年9月19日
  • StubHub Prices Initial Public Offering

    StubHub Holdings, the leading global secondary ticketing marketplace, announced the pricing of its IPO at $23.50 per share, offering over 34 million shares. Trading on the NYSE under “STUB” begins September 17, 2025. J.P. Morgan and Goldman Sachs are leading the offering, which reflects strong investor confidence in the live events sector. StubHub, operating in North America and internationally via viagogo, serves customers globally in multiple languages and currencies, facilitating ticket sales for diverse live events. Its success hinges on navigating competition and leveraging technology.

    2025年9月17日
  • Sidus Space Announces Pricing of Public Offering

    Sidus Space (SIDU) announced a public offering of 9.8 million Class A common shares at $1.00 per share, expecting gross proceeds of $9.8 million. The offering is set to close on September 16, 2025, with ThinkEquity as the sole placement agent. Net proceeds will go towards working capital and general corporate expenses. This capital raise aims to support Sidus Space’s operations and strategic investments amid rising competition in the space technology sector. The offering is based on a shelf registration statement filed with the SEC.

    2025年9月14日
  • AIRO Announces Pricing of Upsized Public Offering

    AIRO Group Holdings, Inc. (NASDAQ: AIRO) announced the pricing of its upsized underwritten public offering of 4,200,000 shares at $18.50 per share, expected to generate $77.7 million in gross proceeds. Underwriters have an option to purchase additional shares. Proceeds will fund strategic growth, potential acquisitions, and repurchase shares from select stockholders. Cantor is the lead book-running manager. AIRO focuses on aerospace, autonomy, and air mobility, targeting drones, avionics, training, and electric air mobility. The registration statement for the offering was declared effective by the SEC on September 10, 2025.

    2025年9月10日
  • Rapport Announces Pricing of Common Stock Offering

    Rapport Therapeutics (RAPP) announced the pricing of its public offering of 9,615,385 shares at $26.00 per share, potentially generating $250 million in gross proceeds. Underwriters have a 30-day option to purchase an additional 1,442,307 shares. The offering, managed by Goldman Sachs, Jefferies, TD Cowen, and Stifel, is expected to close around September 11, 2025. Funds will support the clinical-stage biotech’s work on neurological and psychiatric disorders.

    2025年9月9日